One injection at birth can prevent a rare, potentially devastating hemorrhage, yet increasing numbers of parents are refusing vitamin K for their newborns. New research suggests that as refusals rise, so do cases of vitamin K deficiency and associated bleeding. The science makes a compelling case for prevention, but the controversy raises a more difficult question: Where does parental autonomy end and our responsibility to protect children begin?
Vitamin K, a routine preventive medication, is at increasing risk of being the “baby” thrown out with the proverbial bathwater, as parents and social media increasingly treat neonatal and pediatric medical care as a choose-your-own-adventure.
Born Vulnerable
Vitamin K is essential for producing “procoagulant” factors that work in a cascade to form clots and “plug” leaks in our circulatory system. Newborns often are born with a Vitamin K deficiency and are at a higher risk of bleeding during the first weeks and months of life. Newborns are normally low in Vitamin K because little crosses the placenta, and their intrinsic gut and liver production of Vitamin K-dependent clotting factors is not yet fully established.
The American Academy of Pediatrics identifies causes of Vitamin K deficiency (VKD), including maternal medications that interfere with Vitamin K, such as anticonvulsants, certain antibiotics, and warfarin, an older anticoagulant. Interestingly, in this instance, breast milk, which is also low in Vitamin K, is not helpful, and infants who develop bleeding after the first week have often been exclusively breastfed and have not received prophylaxis.
In clinical practice, the most common cause is no Vitamin K prophylaxis at birth combined with exclusive breastfeeding.
Vitamin K deficiency bleeding (VKDB) is classified into early, occurring within 24 hours of birth and primarily caused by maternal medications; “classical” VKDB, occurring during the first week of life and often presenting as bruising or umbilical bleeding; and late, occurring between one week and 6 months in breastfed children or those with intestinal issues that impair vitamin K absorption. Late VKDB carries a 30% to 60% risk of intracranial hemorrhage, which can result in permanent brain damage, seizures, or death.
When Success Makes Risk Invisible
Vitamin K prophylaxis, like many of our most successful preventive measures (e.g., polio or measles vaccination), may be a victim of its own success, as the rarity of vitamin K deficiency in newborns may leave modern families largely unaware of its grave consequences. Long before COVID’s shadow, the proportion of newborns not receiving intramuscular vitamin K has been rising. A study found that between 2017 and 2024, the percentage rose from 2.9% to 5.2%.
In the words of Steven Woolf, MD, Director emeritus of the Virginia Commonwealth University Center for Society and Health,
“We knew from prior studies that vitamin K refusal had been increasing in the U.S., and we wanted to learn if there were any real-life consequences of this trend.”
Their findings are reported in JAMA Pediatrics, while another group reported on the same dataset in JAMA.
Fewer Injections, More Bleeding
Both studies used a large national database of integrated EPIC electronic health record data (Cosmos), which includes 2300 hospitals and 50,000 outpatient settings to explore the changing incidence of VKD and VKDB between 2017 and 2025. It included all US infants born at 35 weeks’ gestation or later and aged 0 to 6 months. Outcomes included the first diagnosis of VKD or VKDB as well as intracranial or intracerebral hemorrhages.
The researchers found:
- Declining vitamin K administration coincided with substantial increases in diagnosed deficiency and associated bleeding.
The percentage of newborns receiving injectable vitamin K decreased from 97.7% in 2017 to 95.0% in 2025. Over the same period, Vitamin K deficiency (VKD) increased by 216%, from 11.8 to 37.3 cases per 100,000 infants, and Vitamin K–deficient bleeding (VKDB) increased by 347%, from 24.0 to 107.4 cases per 100,000 infants. [1] 6.9% of infants with VKD had documented intracranial or intracerebral hemorrhage, and for infants with VKDB the percentage was 2.4%.
- Only 39.7% of infants diagnosed with VKD and 19.2% of those diagnosed with VKDB had received injectable vitamin K. The greatest increase in VKD and VKDB diagnoses occurred in 2025 at the nadir of vitamin K administration.
While the authors caution that association is not causation, they note that other explanations are unlikely “because behaviors and diseases that increase the risk for VKD remained constant or decreased during this period.”
Is the Prevention Worse Than the Disease?
Concerns have been raised about potential harms from intramuscular vitamin K injections. Some formulations contained phenol, which can cause tumors in animals; however, a systematic review found no increased cancer risk with IM vitamin K. The FDA label on Vitamin K carries a black box warning (the highest level of concern) for allergic reactions and anaphylaxis, primarily from intravenous use. No evidence shows a similar reaction in newborns receiving intramuscular injections.
A historical version from the 1950s was associated with red blood cell damage, resulting in kernicterus, a rare cause of brain damage in newborns from breakdown products in those red blood cells. Phytonadione, the form of Vitamin K given today, has not shown this effect. Vitamin K prophylaxis has an exceptionally favorable safety record in newborns. Serious adverse reactions are possible but appear very rare, while its effectiveness in preventing potentially catastrophic bleeding is well established.
The medical argument for routine prophylaxis
The strongest argument is that a common, predictable vulnerability at birth can be corrected by a relatively safe, inexpensive, one-time intervention. The low absolute numbers of infants affected should not fool us. They reflect the vast majority of children receiving prophylaxis and point to the previously mentioned paradox: having made serious bleeding exceptionally uncommon, it has also made the consequences of refusing treatment less visible.
The medical argument for universal treatment rests on several pillars.
- We cannot reliably identify the subgroup that would benefit from prophylaxis.
- Severe bleeding is unpredictable, and when it occurs during early neurologic development, it may produce lifelong disability. Preventing such a “black swan” outcome is valuable even when its probability is small.
- One injection is far more convenient, providing sustained protection through the vulnerable period, whereas oral prophylaxis requires repeated doses.
These characteristics make routine vitamin K a particularly compelling preventive care.
The Right to Say No
These are primarily ethical considerations that we have struggled with since the pandemic. It is another skirmish in the argument over population versus individual benefit, asking whether a small absolute risk justifies routine intervention for all.
Unlike arguments over vaccination’s population effects, where herd immunity protects others, Vitamin K primarily affects the newborn. [2] The ethical question is consequently more focused: how far should society go to protect a child from a small but preventable risk created by a parent's decision?
Parents routinely make decisions that expose their children to some degree of risk, from recreational activities to choices about nutrition and medical treatment. We do not ordinarily intervene simply because a physician believes a different decision would be better.
Whose Rights Are We Protecting?
The medical evidence strongly supports giving intramuscular vitamin K to every newborn. Physicians should recommend it without equivocation, explaining both the small absolute risk of bleeding and its potentially devastating consequences. When parents decline, our responsibility is to explain the evidence, address their concerns, and preserve the therapeutic relationship rather than allow disagreement to foreclose further discussion.
But a compelling medical recommendation is not necessarily a sufficient justification for coercion. Parents routinely make decisions that expose their children to risk, and we do not ordinarily intervene simply because a physician believes another choice would be better. The difficult question is where that tolerance ends, particularly when the harm is improbable but potentially irreversible.
However, an important asymmetry shapes this debate. Parents exercise the autonomy, but their newborn bears the consequences. Medical autonomy is not unlimited, nor does every medically unwise decision justify state intervention. The challenge is to recognize both truths without diminishing either.
Ultimately, the goal should not be to win an argument over parental authority, but to prevent avoidable harm. That begins with honest communication about risk, an unequivocal, evidence-based recommendation, and recognition that respecting a parent's right to refuse does not require pretending that refusal is an equally safe choice.
[1] In absolute numbers, 2,151 infants were diagnosed with vitamin K deficiency and 5,217 with vitamin K–deficient bleeding.
[2] There are significant medical costs associated with long-term neurologic disability that will fall to the government and therefore the taxpayer.
Source: Vitamin K Deficiency and Associated Bleeding in Infants JAMA Pediatrics DOI: 10.1001/jamapediatrics.2026.5794
Nonreceipt of Newborn Vitamin K and Risk of Bleeding JAMA DOI: 10.1001/jama.2026.21764
Category
